Beam Therapeutics Inc. files Definitive Proxy Statement for 2024 Annual Meeting

TL;DR

<b>Beam Therapeutics Inc. announced its 2024 Annual Meeting of Stockholders to be held virtually on June 5, 2024, to elect a Class I director.</b>

AI Summary

Beam Therapeutics Inc. (BEAM) filed a Proxy Statement (DEF 14A) with the SEC on April 19, 2024. Beam Therapeutics Inc. will hold its 2024 Annual Meeting of Stockholders on June 5, 2024, at 11:30 a.m. EDT. The meeting will be conducted virtually via live webcast at www.virtualshareholdermeeting.com/BEAM2024. The primary purpose of the meeting is to elect Graham Cooper as a Class I director for a three-year term. The filing is a Definitive Proxy Statement (DEF 14A) under the 1934 Act. The company's principal executive offices are located at 26 Landsdowne Street, Cambridge, MA 02139.

Why It Matters

For investors and stakeholders tracking Beam Therapeutics Inc., this filing contains several important signals. This filing provides shareholders with crucial information regarding the upcoming annual meeting, including the agenda and director nominations, enabling informed voting decisions. As a DEF 14A filing, it details executive compensation and other governance matters, offering transparency into the company's management and operational direction.

Risk Assessment

Risk Level: low — Beam Therapeutics Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would alter the company's risk profile.

Analyst Insight

Shareholders should review the proxy statement to understand the director nominee and any other proposals before the June 5, 2024, annual meeting.

Key Numbers

• June 5, 2024 — Annual Meeting Date (Date of the 2024 Annual Meeting of Stockholders.)
• 11:30 a.m. EDT — Annual Meeting Time (Time of the 2024 Annual Meeting of Stockholders.)
• 2027 — Director Term End (Year until which Graham Cooper will serve as Class I director.)

Key Players & Entities

• Beam Therapeutics Inc. (company) — Registrant name and company filing the proxy statement.
• Graham Cooper (person) — Nominee for Class I director.
• June 5, 2024 (date) — Date of the 2024 Annual Meeting of Stockholders.
• 26 Landsdowne Street, Cambridge, MA 02139 (address) — Company's business and mailing address.
• DEF 14A (document_type) — Form type of the filing.
• 1934 Act (regulation) — Securities Exchange Act under which the filing is made.

FAQ

Industry Context

Beam Therapeutics Inc. is a biotechnology company focused on developing genetic medicines. This filing pertains to corporate governance and shareholder matters.

Regulatory Implications

The filing is made under Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies from shareholders.

What Investors Should Do

1. Review the proxy statement for details on the director nominee, Graham Cooper.
2. Vote on the election of Graham Cooper and any other proposals at the Annual Meeting.
3. Ensure your proxy is submitted by the deadline for the June 5, 2024, meeting.

Key Dates

• 2024-06-05: 2024 Annual Meeting of Stockholders — To elect directors and vote on other company matters.

Year-Over-Year Comparison

This is a DEF 14A filing for the 2024 Annual Meeting, following previous filings related to corporate actions and disclosures.

Filing Documents

• beam-20240419.htm (DEF 14A) — 1346KB
• img43955338_0.jpg (GRAPHIC) — 5KB
• img43955338_1.jpg (GRAPHIC) — 3KB
• img43955338_2.jpg (GRAPHIC) — 5KB
• img43955338_3.jpg (GRAPHIC) — 223KB
• img43955338_4.jpg (GRAPHIC) — 213KB
• img43955338_5.jpg (GRAPHIC) — 461KB
• img43955338_6.jpg (GRAPHIC) — 240KB
• 0000950170-24-046017.txt (&nbsp;) — 4507KB
• beam-20240419.xsd (EX-101.SCH) — 34KB
• beam-20240419_htm.xml (XML) — 110KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 26 PAY VERSUS PERFORMANCE 37 DIRECTOR COMPENSATION 40 AUDIT COMMITTEE REPORT 42 DELINQUENT SECTION 16(a) REPORTS 43 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 44 PROPOSAL NO. 1—ELECTION OF DIRECTOR 46 PROPOSAL NO. 2—RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 47 PROPOSAL NO. 3—ADVISORY VOTE ON NAMED EXECUTIVE OFFICER COMPENSATION 49 TRANSACTION OF OTHER BUSINESS 50

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 51 SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS 53 GENERAL MATTERS 54 BEAM THERAPEUTICS INC. 238 Main Street Cambridge, MA 02142 PROXY STATEMENT FOR 2024 ANNU AL MEETING OF STOCKHOLDERS To Be Held on June 5, 2024 The Board of Directors (our "Board") of Beam Therapeutics Inc. ("we," "us," "our," "Company," or "Beam") is soliciting proxies from stockholders for its use at the 2024 annual meeting of our stockholders (the "Annual Meeting"), and at any continuation, postponement or adjournment of that meeting. The Annual Meeting is scheduled to be held on June 5, 2024, at 11:30 a.m., Eastern Daylight Time, in a virtual meeting format at www.virtualshareholdermeeting.com/BEAM2024 . There will not be a physical meeting location, and stockholders will not be able to attend the Annual Meeting in person. Further information about how to attend the Annual Meeting online is included in this proxy statement. All properly submitted proxies will be voted in accordance with the instructions contained in those proxies. If no instructions are specified, the shares represented by the proxies will be voted in accordance with the recommendation of our Board with respect to each of the matters set forth in the accompanying Notice of Meeting. If you are a stockholder of record, you may change your vote or revoke your proxy at any time before it is exercised at the Annual Meeting by following the instructions set forth in this proxy statement. On or about April 19, 2024, we will commence sending the Important Notice Regarding the Availability of Proxy Materials (the "Notice") to all stockholders entitled to vote at the Annual Meeting. IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS This proxy statement and our 2023 Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the Securities and Exchange Commission (the "SEC") on February